Status:
UNKNOWN
The Impact of Covid-19 Hospital Care on the Prevalence of MDRO in Indonesia
Lead Sponsor:
Erasmus Medical Center
Collaborating Sponsors:
British Society for Antimicrobial Chemotherapy
University of Brawijaya
Conditions:
Antibiotic Resistant Infection
COVID-19
Eligibility:
All Genders
19+ years
Brief Summary
The effect of the COVID-19 pandemic on the emergence and spread of antibiotic-resistant bacteria is largely unknown, especially in low-resource settings. We aim to investigate the prevalence and relat...
Detailed Description
The overall objective of the study is to reveal the impact of hospital care for COVID-19 patients on the prevalence of MDRO among COVID-19 patients, compared to non-COVID-19 hospital care and the prev...
Eligibility Criteria
Inclusion
- All adult patients discharged from Covid wards and non Covid wards (ICU and internal medicine wards)
Exclusion
- Patients discharged within 48 hours of admission
- Patients who either live outside the city of Malang or their address is unclear
Key Trial Info
Start Date :
March 7 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 7 2023
Estimated Enrollment :
1110 Patients enrolled
Trial Details
Trial ID
NCT05293483
Start Date
March 7 2022
End Date
March 7 2023
Last Update
March 24 2022
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Ngudi Waluyo hospital
Blitar, East Java, Indonesia
2
dr. Saiful Anwar hospital
Malang, East Java, Indonesia, 65111